- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04115514
Traitement du SDRA avec T3 instillé (ARDS+T3)
Étude randomisée de phase II, intervention versus non-intervention, étude multicentrique des effets de l'hormone thyroïdienne (T3) sur l'eau pulmonaire extravasculaire (EVLW) chez des sujets atteints du syndrome de détresse respiratoire aiguë (SDRA)
It is hypothesized that instillation of Liothyronine Sodium (T3) into the airspace will be safe, well tolerated, and will increase alveolar fluid clearance and decrease inflammation in patients with ARDS, reflected in improved oxygenation index (OI) and oxygenation saturation index (OSI).
Aperçu de l'étude
Statut
Les conditions
Description détaillée
T3 Therapy in ARDS- Phase 2 Randomized, Unblinded, Intervention versus Non- Intervention Trial. Enrollment 68 participants (50 treatment + 18 control). Purpose- To determine the safety and tolerability of T3 delivery into the lungs of ARDS patients, and to measure the effect of T3 on Oxygenation in ARDS patients. Study Drug- Liothyronine Sodium (T3), 50 mcg will be instilled twice daily via a catheter through the ETT into the airway in a total volume of 10 mL (T3+0.9% sodium chloride), over 5 days (10 total doses), or until extubation, whichever comes first.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Minnesota
-
Edina, Minnesota, États-Unis, 55435
- M Health Fairview Southdale Hospital
-
Minneapolis, Minnesota, États-Unis, 55455
- East Bank Hospital - M Health Fairview University of Minnesota Medical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Study population is critically ill patients requiring mechanical ventilatory support for ARDS in an intensive care unit.
-
Adults (≥18 years of age).
-
Male or female (non-pregnant).
-
Clinical diagnosis of ARDS (all are required):
- Onset: <= 7 days.
- Chest x-ray: Bilateral Patchy Opacities, Infiltrates.
- Mechanical Vent Support: PEEP or CPAP Support >= 5 cm H2O.
- Pulmonary Edema: Not fully explained by cardiogenic etiology.
- Hypoxia: PaO2/FIO2 Ratio <300, or O2Sat/FIO2 Ratio <315.
-
On mechanical ventilatory support.
-
Capable of giving informed consent directly or from the subject's legally authorized representative (LAR) as determined by the site Principal Investigator and/or Sub- Investigators.
Exclusion Criteria:
Patients with any of the following conditions will be excluded from this trial:
-
Inadequate medical history for determining inclusion/exclusion criteria, as determined by the Principal Investigator and/or Sub- Investigators.
-
Unlikely to complete the protocol with clinic follow-up after discharge, as determined by the Principal Investigator and/or Sub- Investigators or hospice status.
-
Prior history of thyroid cancer or hyperthyroidism, per thorough patient/family interviews, review of past medical history, medication list, laboratory test.
-
Prior history of cardiovascular disease defined as:
- Hypertensive crisis in the past 3 months (systolic >200, or diastolic >120 mmHg),
- Sustained ventricular arrhythmia in the past 3 months (duration >30 seconds)
- Coronary artery disease (documented >=70% occlusion untreated in any coronary vessel), as per the 2021 ACC/AHA/SCAI Guidelines for Coronary Artery Revascularization.
- Cardiac-related angina pectoris (>=2 episodes in the past 3 months)
- Myocardial infarction with ischemia on ECG (i.e.,new ST- elevation/depression of >1mm in contiguous leads).
- Peripheral vascular disease (documented >=70% occlusion untreated in any peripheral vessel), as per the 2018 ACC/AHA/SCAI/SIR/SVM Guidelines for Appropriate Use Criteria for Peripheral Artery Intervention.
- Decompensated or symptomatic heart failure (i.e., hospitalized for CHF exacerbation, or a change in CHF medications within two weeks prior)
-
Currently pregnant or breastfeeding.
-
Known allergy to study drug.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Treatment Arm
Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation. |
Study Drug Administration:
|
|
Autre: Control arm
Standard of Care |
Standard of Care (SOC) |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Délai: baseline
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
baseline
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Délai: 6 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
6 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Délai: 12 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
12 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Délai: 24 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
24 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Délai: 48 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
48 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Délai: 72 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
72 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Délai: 96 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
96 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
Délai: 120 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
120 hours post-dose
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Dose(s) de presseur(s) SOC
Délai: référence et 5 jours
|
référence et 5 jours
|
|
|
Dose(s) de diurétique(s) SOC
Délai: référence et 5 jours
|
référence et 5 jours
|
|
|
Jours sans ventilateur
Délai: référence et 5 jours
|
référence et 5 jours
|
|
|
Journées gratuites aux soins intensifs
Délai: référence et 5 jours
|
référence et 5 jours
|
|
|
Journées sans oxygène
Délai: référence et 5 jours
|
référence et 5 jours
|
|
|
Mortalité toutes causes confondues
Délai: référence et 5 jours
|
référence et 5 jours
|
|
|
Exigence de placement de trachéotomie
Délai: référence et 5 jours
|
référence et 5 jours
|
|
|
TSH, T3 totale, T3 gratuite, T4 gratuite
Délai: au départ et 156 heures après l'administration
|
au départ et 156 heures après l'administration
|
|
|
T3 gratuit, T4 gratuit
Délai: référence et 5 jours
|
référence et 5 jours
|
|
|
Pulmonary events
Délai: baseline and 120 hours post-dose
|
Progressive hemoptysis: bright, red blood in streaks, mixed or clots within sputum on suctioning of greater than 30 mL accumulation anytime following the initial and subsequent intratracheal dosing administrations. |
baseline and 120 hours post-dose
|
|
Cardiovascular event 1
Délai: baseline to 120hours post-dose
|
New sustained ventricular arrhythmia (>30 secs) |
baseline to 120hours post-dose
|
|
Cardiovascular event 2
Délai: baseline to 120hours post-dose
|
New sustained accelerated junctional arrhythmia (rate >80 bpm) with worsened hypotension (decrease in mean arterial pressure to less than 65mmHg). |
baseline to 120hours post-dose
|
|
Cardiovascular event 3
Délai: baseline to 120hours post-dose
|
New sustained atrial fibrillation with rapid ventricular response (ventricular rate >160 bpm) with worsened hypotension (decrease in mean arterial pressure to less than 65mmHg). |
baseline to 120hours post-dose
|
|
Cardiovascular event 4
Délai: baseline to 120hours post-dose
|
Cardiac arrest (pulseless electrical activity, or asystole). |
baseline to 120hours post-dose
|
|
Cardiovascular event 5
Délai: baseline to 120hours post-dose
|
Hypertensive crisis (systolic pressure of 180 mmHg (or higher), or diastolic pressure of 120 mmHg (or higher) or change in MAP > 20 mmHg with three consecutive measurements over 30 minutes). |
baseline to 120hours post-dose
|
|
SOC pulmonary vasodilator
Délai: baseline and 5 days
|
yes or no |
baseline and 5 days
|
|
Supplemental oxygen on discharge
Délai: baseline and 5 days
|
yes or no |
baseline and 5 days
|
|
Discharge disposition
Délai: baseline and 5 days
|
home, inpatient rehabilitation, long-term acute care hospital (LTACH) |
baseline and 5 days
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: David H Ingbar, MD, University of Minnesota
- Directeur d'études: Timothy P Rich, MD, University of Minnesota
- Chercheur principal: Ronald A Reikoff, MD, University of Minnesota
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système endocrinien
- Infections des voies respiratoires
- Infections
- Maladies des voies respiratoires
- Maladies pulmonaires
- Troubles respiratoires
- Maladies thyroïdiennes
- Syndrome de détresse respiratoire
- Œdème pulmonaire
- Pneumonie
- Hormones
- Hormones, substituts hormonaux et antagonistes hormonaux
- Acides aminés, peptides et protéines
- Acides aminés
- Acides aminés, aromatique
- Acides aminés, cyclique
- Hormones thyroïdiennes
- Thyronines
- Thyroxine
- Triiodothyronine
Autres numéros d'identification d'étude
- PACS-2020-23242
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .